Adaptimmune Therapeutics (ADAP) has issued an announcement.
Adaptimmune Limited and Galapagos NV have embarked on a promising collaboration, initiating a clinical trial to test a novel T-cell therapy for head & neck cancer. The agreement nets Adaptimmune $70 million upfront plus potential milestone payments up to $465 million and royalties on future sales. While Galapagos gains exclusive licensing options, Adaptimmune retains rights for its therapy in treating ovarian cancer. This strategic partnership could revolutionize cancer treatment and offers financial upside for both companies.
For detailed information about ADAP stock, go to TipRanks’ Stock Analysis page.
